# CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

> **NCT03896269** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 38 (estimated)

## Conditions studied

- Blasts 10-19 Percent of Bone Marrow Nucleated Cells
- Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
- High Risk Chronic Myelomonocytic Leukemia
- Recurrent Chronic Myelomonocytic Leukemia
- Recurrent High Risk Myelodysplastic Syndrome
- Refractory Chronic Myelomonocytic Leukemia
- Refractory High Risk Myelodysplastic Syndrome

## Interventions

- **DRUG:** Liposome-encapsulated Daunorubicin-Cytarabine

## Key facts

- **NCT ID:** NCT03896269
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-05-14
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03896269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03896269, "CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03896269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*